Defence Therapeutics Opens 1 Office in Hamilton Radiopharma Hub to Advance Precision Oncology

For healthcare leaders, the expansion signals growing infrastructure readiness for radiopharmaceutical deployment. As targeted radioligand therapies move closer to clinical use, access to isotope production and translational research hubs like Hamilton becomes critical for ensuring timely patient access and treatment scalability.

Defence Therapeutics, a publicly traded biotechnology company, has taken a strategic step to bolster its radiopharmaceutical ambitions by opening a new office at McMaster Innovation Park in Hamilton, Ontario. The move, announced on July 8, 2026, positions Defence within one of Canada’s premier radiopharmaceutical clusters, anchored by McMaster University and a burgeoning ecosystem of isotope production, translational research, and GMP manufacturing. The company, trading on the Canadian Securities Exchange (DTC), OTCQB (DTCFF), and Frankfurt Stock Exchange (DTC), aims to leverage this hub to accelerate its proprietary Accum technology—a platform designed to enhance the delivery and efficacy of precision oncology therapeutics. This expansion underscores the growing importance of targeted radiopharmaceuticals in cancer treatment, a field where location-specific expertise can significantly shorten development timelines and attract partnerships.

“

Defence Therapeutics, a publicly traded biotechnology company, has taken a strategic step to bolster its radiopharmaceutical ambitions by opening a new office at McMaster Innovation Park in Hamilton, Ontario.

The radiopharmaceutical market has been gaining momentum as targeted alpha and beta therapies offer new hope for cancers resistant to conventional treatments. By situating itself in Hamilton, Defence gains proximity to McMaster’s nuclear reactor—Canada’s primary source of medical isotopes—and a talent pool steeped in radiochemistry and nuclear medicine. The McMaster Innovation Park, home to a growing community of life sciences innovators, provides specialized infrastructure that supports the entire value chain from discovery to clinical translation. CEO Sébastien Plouffe highlighted that the expansion reflects the company’s internal growth and the increasing momentum of its radiopharmaceutical programs, emphasizing the opportunity to build collaborations and access exceptional expertise. This strategic alignment is crucial for Defence, which aims to differentiate its Accum platform in a competitive landscape that includes established players like Novartis and Bayer, as well as emerging biotechs focused on radioligand therapies.

The Accum platform itself is designed to improve the intracellular targeting of therapeutic molecules, potentially enhancing the potency of radiopharmaceuticals while reducing off-target toxicity. While still in preclinical or early clinical stages, the platform’s promise hinges on robust translational research capabilities—the very resources now readily available in Hamilton. Defence’s decision to open an office rather than just establish a virtual presence signals a long-term commitment to integrating into the local innovation fabric, which could lead to joint research initiatives, licensing deals, or even future manufacturing partnerships. The move also comes as global investment in radiopharma surges, with recent deals and funding rounds valuing the sector in the billions, driven by promising clinical data in prostate and neuroendocrine cancers.